ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Cingulate Inc

Cingulate Inc (CING)

0.43
-0.0504
(-10.49%)
Closed July 14 4:00PM
0.4393
0.0093
(2.16%)
After Hours: 7:45PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.4393
Bid
0.4132
Ask
1.03
Volume
1,459,613
0.4131 Day's Range 0.4874
0.284 52 Week Range 17.112
Market Cap
Previous Close
0.4804
Open
0.45
Last Trade
81
@
0.4549
Last Trade Time
Financial Volume
$ 639,145
VWAP
0.437887
Average Volume (3m)
460,634
Shares Outstanding
6,046,479
Dividend Yield
-
PE Ratio
-0.11
Earnings Per Share (EPS)
-3.89
Revenue
-
Net Profit
-23.54M

About Cingulate Inc

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions cha... Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Cingulate Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CING. The last closing price for Cingulate was $0.48. Over the last year, Cingulate shares have traded in a share price range of $ 0.284 to $ 17.112.

Cingulate currently has 6,046,479 shares outstanding. The market capitalization of Cingulate is $2.90 million. Cingulate has a price to earnings ratio (PE ratio) of -0.11.

CING Latest News

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug...

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Twelve Required Registration Batches CompletedNew Drug Application Being Prepped for Submission KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug...

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application        CTx-1301 Could Benefit >60% of ADHD Patients Currently Using Immediate-Release Booster Doses Advancing...

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders’ Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

$17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.111333.93292682930.3280.750.318157140.48219385CS
4-0.2418-35.50139480250.68110.750.2848984580.40724312CS
12-0.4024-47.80800760370.84171.160.2844606340.5661219CS
26-6.3107-93.49185185196.757.370.2843742331.0678736CS
52-15.5607-97.2543751617.1120.2846194455.26487855CS
156-99.5607-99.56071001030.28442097717.29024942CS
260-99.5607-99.56071001030.28442097717.29024942CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.65M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

CING Discussion

View Posts
StockItOut StockItOut 3 days ago
Yet again Hans Brost @Zardiw bullshit claims that prior to a runner running his "DDAmanda finds runners" yet he only posts after a huge breakout and then afterwards looks at the DDAmanda trading numbers from days before claiming his scan found the runner days before. But Hans Brost Zardiw does not actually enter the trade.

Why by implication do you lie Hans?

Did you enter the trade to buy CING at the lows right before the breakout?

Seems you do a scan, and then you backwards claim a days prior entry that you in fact do not enter.

If so good, you'd make money on near every scan... but you don't even buy in.
👍️0
Zardiw Zardiw 4 days ago
$CING +107% #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z
👍️0
Monksdream Monksdream 2 weeks ago
Whoops, I did it, again
👍️0
PonkenPlonken PonkenPlonken 2 weeks ago
I think that is because the company comes close to a scam. They claimed blockbuster drug in ADHD, in reality people dont want such a long lasting compound. They created a product for a very small subgroup of ADHDers.
If they owned the PTR platform, there would be something here because its great... but they licensed it.
👍️0
Monksdream Monksdream 2 weeks ago
CING new 52 week low
👍️0
Monksdream Monksdream 4 weeks ago
CING new 52 week low
👍️0
juggernutt juggernutt 1 month ago
Real quiet here
👍️0
juggernutt juggernutt 1 month ago
Sorry wrong board
👍️0
juggernutt juggernutt 1 month ago
News out
👍️0
tbonaces80 tbonaces80 1 month ago
Miax needs to cover. Let’s hit the ask. Make them chase
👍️0
Bucvkdawg2025 Bucvkdawg2025 1 month ago
Ok dick! I do my own ... but your continued comments never have any reference to them so it appears your research is misleading or BS.
👍️0
tbonaces80 tbonaces80 1 month ago
Do ur own research brah
👍️0
Bucvkdawg2025 Bucvkdawg2025 1 month ago
Based off what source? And when will this come out in the news?
👍️0
tbonaces80 tbonaces80 2 months ago
New partner on deck. Just waiting. This is their opportunity to impress the stock price
👍️0
stock1ace1 stock1ace1 2 months ago
Huh?
👍️0
tbonaces80 tbonaces80 2 months ago
Regained NAZ compliance
👍️0
stock1ace1 stock1ace1 2 months ago
.76 fills thanks mms
👍️0
stock1ace1 stock1ace1 2 months ago
Mm buying 100 lots they need shares looks like !
👍️0
stock1ace1 stock1ace1 2 months ago
Company Is Seeking Licensing Partners News Watch->

“”We also believe this communication provides additional go-to-market momentum as we continue to meet with potential partners for the outlicensing of CTx-1301 in the United States and abroad.””






FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Source: GlobeNewswire Inc.

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it has received confirmation from and is aligned with the U.S. Food and Drug Administration (FDA) on the requirements necessary for filing a New Drug Application (NDA) for its lead Phase 3 candidate CTx-1301 (dexmethylphenidate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients six years of age or older.
Details from the FDA communication to Cingulate include the following:

Per the 505(b)(2) pathway, submission of CTx-1301’s NDA does not require continuation of the fixed dose study and the onset and duration study;
Data collected to date from these two Phase 3 studies will be included in the filing; and
Contemporaneously with the preparation of the NDA filing, Cingulate will conduct a Phase 1 fed/fast study, the study is expected to last approximately two to three weeks, with the results being included in the NDA filing.
“We are pleased with the FDA’s guidance and perspective regarding our pathway to a timely NDA filing, and we will proceed to complete all remaining requirements accordingly,” said Cingulate Chairman and CEO Shane J. Schaffer. “We also believe this communication provides additional go-to-market momentum as we continue to meet with potential partners for the outlicensing of CTx-1301 in the United States and abroad. Now that we have a clear path to submission, we look forward to engaging with key payer stakeholders to achieve maximum access and market penetration to benefit ADHD patients and their families.”

Cingulate has begun NDA preparation and expects to submit its filing in the first half of 2025.

Ann Childress, M.D., President, Center for Psychiatry and Behavior Medicine, Inc., and lead investigator of Cingulate’s CTx-1301 onset and duration study, stated, “The treatment effect size of CTx-1301 was remarkable given the current effect sizes observed in the marketplace. Many patients require longer duration of efficacy and must add a second, or booster, dose to ensure treatment effect over their entire active day. The patients I observed, once notified they were taking CTx-1301, have expressed a desire to remain on the medication after the trial concluded.”

“If approved,” Childress continued, “I believe CTx-1301 could potentially benefit the more than 60 percent of patients currently using immediate-release booster doses to extend the efficacy of their medications.”

Earlier this year, Cingulate presented results from the Phase 3 adult efficacy and safety study of CTx-1301 at the 2024 American Professional Society of ADHD and Related Disorders (APSARD) conference in Orlando, FL.

The results were previously presented at the 2023 Psych Congress, where a poster describing the data was selected as a finalist for the Psych Congress’s First Annual Poster Awards.

The Cingulate poster presented at APSARD provided additional insight regarding CTx-1301’s ADHD leading effect size. Effect size conveys clinical significance rather than statistical significance, is not reliant on sample size, and allows for comparison across trials. The poster presented may be viewed here.

About Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., approximately 6.4 million children and adolescents (11 percent) aged under the age of 18 have been diagnosed with ADHD. Among this group, approximately 80 percent receive treatment, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Adult ADHD prevalence is estimated at approximately 11 million patients (4.4 percent), almost double the size of the child and adolescent segment combined. However, only an estimated 20 percent receive treatment.

About CTx-1301
Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. While stimulants are the gold standard of ADHD treatment due to their efficacy and safety, the long-standing challenge continues to be providing patients with an entire active-day duration of action. CTx-1301 is designed to precisely deliver three releases of medication at the predefined time, ratio, and style of release to optimize patient care in one tablet. The result is a rapid onset and entire active-day efficacy, with the third dose being released around the time when other extended-release stimulant products begin to wear off.

About Precision Timed Release™ (PTR™) Platform Technology
Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the core tablet. The EBL formulation, Oralogik™, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition to Anxiety and ADHD where one or more active pharmaceutical ingredients need to be delivered several times a day at specific, predefined time intervals and released in a manner that would offer significant improvement over existing therapies. To see Cingulate’s PTR Platform, click here.

About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of attention deficit/hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on April 1, 2024. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Investor Relations
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/00c8b334-57ec-49cf-9a59-02d75463089e
👍️0
tbonaces80 tbonaces80 2 months ago
Every buy is about :26 seconds to “quietly accumulate”. MIAX buying. L3 on my BB terminal
👍️0
tbonaces80 tbonaces80 2 months ago
Gonna pop.
👍️0
tbonaces80 tbonaces80 2 months ago
MIAX is long.
👍️0
cdiddy01 cdiddy01 2 months ago
Yah, by whom? Who tells u these things?
👍️0
tbonaces80 tbonaces80 2 months ago
HC Wainwright will up their target with additional analyst coverage I’m told
👍️0
tbonaces80 tbonaces80 2 months ago
Next up. Partnership pipeline.
👍️0
tbonaces80 tbonaces80 2 months ago
We are MM. powwww
👍️0
tbonaces80 tbonaces80 2 months ago
We break .8380 and off we go. The sales were planned between lake from the s-1. We have almost traded the entire float (6.57m); if they even sold the additional 2m shares. I doubt it but this am was possible. Someone accumulated all of it. Double down here.
👍️0
Roadtojourney Roadtojourney 2 months ago
My avg is a bit higher, bit ok to hold. Slowly it will start crawling up..imo??
👍️0
tbonaces80 tbonaces80 2 months ago
We are buying
👍️0
Roadtojourney Roadtojourney 2 months ago
Seems like sell on news today??
👍️0
tbonaces80 tbonaces80 2 months ago
This is a double digit stock. Minimum $8
👍️0
tbonaces80 tbonaces80 2 months ago
Angel investor going to enfuse.
👍️0
tbonaces80 tbonaces80 2 months ago
Locked and not selling. This will be more than an ADHD company. Think 5-10 out of
👍️0
tbonaces80 tbonaces80 2 months ago
News on deck from Vegas and FDA submission
👍️0
tbonaces80 tbonaces80 2 months ago
Cash infusion, Tender Offer or private placement with either BDD or Chemwerth Inc.
👍️0
juggernutt juggernutt 2 months ago
Volume up too
👍️0
ckmseven788 ckmseven788 2 months ago
Nice buys coming in.
👍️0
tbonaces80 tbonaces80 2 months ago
Last time you will see cents and single dollars.
👍️0
ckmseven788 ckmseven788 2 months ago
CING back over $1.00. Starting to form a base.
👍️0
tbonaces80 tbonaces80 2 months ago
Broke outside top KG band. Reversal definitely showing here. Load it up
👍️0
tbonaces80 tbonaces80 2 months ago
Definitive agreement should be announced Friday showing $5-10m cash infusion and ramp up on clinical.
👍️0
tbonaces80 tbonaces80 2 months ago
Gonna break $2 on expected cash flow. $30 stock easy
👍️0
tbonaces80 tbonaces80 3 months ago
Pending definitive agreement will be inked. $5-$10m which will cover the NDA fees of roughly $3.6m. Back that into the S/P makes it an $8 stock alone hence why HC wainwright has an estimate at $8. Couldn’t be easier
👍️0
tbonaces80 tbonaces80 3 months ago
233 shareholder as of 12/2023 and 1.167M shares. This thing is a 30-50x based on NDA filing. This is a gem.
👍️0
tbonaces80 tbonaces80 3 months ago
Gobble up. Buy stops sitting at $1.02.
👍️0
tbonaces80 tbonaces80 3 months ago
Funding of $5-10m in deck
👍️0
tbonaces80 tbonaces80 3 months ago
Loading all over here
👍️0
tbonaces80 tbonaces80 3 months ago
Well not the sexiest news but….
👍️0
tbonaces80 tbonaces80 3 months ago
The last flush. Expect PR tomorrow
👍️0
tbonaces80 tbonaces80 3 months ago
Shayne says expect the update. Have your buy stops in.
👍️0

Your Recent History

Delayed Upgrade Clock